

Manuscript

ID: 82802

Manuscript title: Infliximab versus Adalimumab: Points to Consider When Selecting Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Crohn's Disease

REVIEWERS' COMMENTS TO AUTHOR:

Reviewer:

REVIEWER COMMENT	AUTHOR RESPONSE	PAGE NUMBER
<p>1. Indications can include at what point the anti TNF to be commenced [within <3 months after diagnosis - higher corticosteroid- and surgery-free remission rates at 1 year than induction with EEN or corticosteroids followed by immunomodulator therapy]</p>	<p>Thank you for your comment. We added the indications for early induction of anti-TNF agents and outcomes of top-down therapy. “ However, the guidelines recently published by the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) recommended early anti-TNF treatment within <3 months after diagnosis for the induction of remission in moderate-to-severe pediatric CD with a high risk of complications such as extensive disease, deep colonic ulcers, perianal disease, stricturing [B2], or penetrating disease [B3], growth impairment, the so-called top-down strategy[20]. The RISK study demonstrated that early induction therapy with anti-TNF agents was associated with higher corticosteroid- and surgery-free remission rate at 1 year compared to induction with EEN and corticosteroids. Kugathasan et al. also reported that early induction therapy with anti-TNF agents significantly lowered the risk of penetrating [B3] complications, however did not seem to reduce the risk of stricturing [B2] complications.”</p>	<p>Page 6-7, line 126-136</p>
<p>2. Also, other indicative features to be considered such as those who do not reach clinical [PCDAI <</p>	<p>Thank you for your recommendation. As you pointed out, we added the additional indication of anti-TNF agents.</p>	<p>Page 7, line 136-139</p>

<p>10] and biochemical remission [faecal calprotectin <250 µg/g] after induction with EEN or corticosteroids</p>	<p>“In addition, even in patients with low risk of poor outcome, anti-TNF therapy should be considered in patients with severe growth impairment or who have not achieved clinical [Pediatric Crohn’s disease activity index (PCDAI) <10] and biochemical remission [faecal calprotectin <250 µg/g] despite induction therapy with EEN or corticosteroids.”</p>	
<p>3. Any dosing modifications to be done based on the weight / other investigations [children < 30 kg, and those with extensive disease and low serum albumin levels, require higher induction doses up to 10 mg/kg, shorter dosing intervals, or both, to reach target trough levels]</p>	<p>Thank you for your comment. We revised our manuscript as your recommendation and added the indication of dose escalation in induction phase. “Especially, children at risk for accelerated IFX clearance during induction [i.e., patients < 30kg, those with extensive disease, and those with low serum albumin] require dose escalation to achieve target trough levels (TLs) or their first proactive therapeutic drug monitoring (TDM) at the second or third anti-TNF infusion”</p>	<p>Page 8, line 159-162</p>
<p>4. Use of Methotrexate in addition to Azathioprin has been noted in literature.</p>	<p>Thank you for your critical comments. We added information on methotrexate and infliximab combination therapy to the manuscript in terms of anti-drug antibodies development. “ For patients starting on IFX, combination therapy with IMM including azathioprine (AZA) and methotrexate (MTX) is recommended.~ Likewise, it was revealed that the combination of IFX plus MTX had a lower ADA development [4% vs. 20%, <i>P</i> = 0.01] and higher IFX TLs [6.35 µg/mL vs. 3.75 µg/mL, <i>P</i> = 0.08] than IFX monotherapy in the COMMIT trial conducted in adult.[72] ~ Similarly, pediatric studies comparing combination of IFX plus IMM (including AZA and MTX) and IFX monotherapy reported results similar to those in adult studies.[59,74,75]”</p>	<p>Page 16-17, line 368~389</p>
<p>5. Practical guidelines of when to combine immunomodulators, end point and outcome can be added [patients with perianal disease, stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front anti-TNF agents in combination with an immunomodulator]</p>	<p>Thank you for your comment. We added the indication of up-front anti-TNF + immunomodulators in our manuscript as your recommendation. “ Therefore, up-front anti-TNF agents in combination with IMMs should be considered in patients with high risk of poor outcomes such as perianal disease, structuring [B2] or penetrating [B3] disease behaviour or severe growth impairment.”</p>	<p>Page 17, line 387-392</p>
<p>6. Monitoring of drug levels (well within the target range and treatment targets) andscopy findings (endoscopic and transmural healing) serve as excel</p>	<p>Thank you for your comment. We agree that TDM, fecal calprotectin and endoscopic findings are considered to be important tools for evaluating endoscopic remission. Therefore, we revised our manuscript</p>	<p>Page 10, line 222-224 Page 13, line 280-283</p>

lent tools.

as follows:

“Although the cut-off values of post-induction TLs for regulating the inflammatory burden at anti-TNF initiation are different for IFX and ADL, it is anticipated that the higher the post-induction TLs, the higher the clinical and endoscopic remission rate.”

“As can be inferred from the above studies, clinical remission and endoscopic healing can be achieved when the drug concentrations are sustained above the threshold despite the difference in the cut-off values for withstanding the inflammatory burden in the maintenance phase between IFX and ADL.”

However, as our review article focused the difference between IFX and ADL, not general management of pediatric CD, methods for assessing and predicting endoscopic remission were not described in detail.

7. Guidelines in the form of algorithms would provide a quick grasp / summary of the review.

Thank you for your recommendation. As your recommendation, we summarized our manuscript in Figure 3.




Figure 3